The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer

Oncology
T FehmW Jäger

Abstract

The relationship between c-erbB-2 serum positivity and prognosis was evaluated in 80 patients with metastatic breast cancer. Using 120 fmol/ml as a cutoff level, elevated concentrations were found in 31 patients (38.8%) at the time of detection of metastases. Menopausal status, steroid receptor status, site of recurrence, initial tumor size, initial degree of nodal involvement as well as relapse-free interval were unrelated to c-erbB-2 serum positivity. In addition, no association could be found between adjuvant chemotherapy and positive c-erbB-2 concentrations. Patients with elevated c-erbB-2 levels showed a lower response rate (including complete remission, partial remission, no change) to first-line therapy than those with normal levels (29 vs. 59%, p < 0.01). The median survival time after relapse was 12 months (CI: 3-22 months) for the c-erbB-2-negative patients and only 6 months (CI: 3-8 months) for the c-erbB-2-positive group (p < 0.01). In the multivariate analysis, while c-erbB-2 levels at the time of primary surgery had no significant impact on survival in metastatic breast cancer, serum c-erbB-2 turned out to be the strongest factor for predicting survival after relapse.

Citations

Jul 6, 2000·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·D Yu, M C Hung
Oct 23, 2001·Breast Cancer : the Journal of the Japanese Breast Cancer Society·H YamauchiD F Hayes
Jun 12, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ralph G ZinnerRoy S Herbst
Jul 27, 2002·Cancer Letters·Andrew RundleFrederica P Perera
Mar 5, 1999·Breast Cancer Research and Treatment·V StearnsD F Hayes
Mar 15, 2006·Nature Medicine·Hongtao ZhangMark I Greene
Dec 11, 2002·The Lancet Oncology·John CrownMartine Piccart
Nov 16, 2010·La Presse médicale·Carole MathelinChristian Koehl
Jun 14, 2002·Seminars in Oncology·Daniel F Hayes, Ann D Thor
Jun 25, 2008·Methods : a Companion to Methods in Enzymology·Jaclyn A FreudenbergHongtao Zhang
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexandra F LearyMitch Dowsett
Oct 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lyndsay HarrisUNKNOWN American Society of Clinical Oncology
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maha H A HussainUNKNOWN National Cancer Institute
Feb 6, 2004·Molecular & Cellular Proteomics : MCP·Jeffrey S RossGabriel N Hortobagyi
Apr 7, 2012·International Journal of Breast Cancer·Sahar ShojaeiAbbas Rahimi Shamabadi
Jun 24, 2015·The Oncologist·Elisabeth J DiverWhitfield B Growdon
Aug 5, 2003·The Oncologist·Jeffrey S RossKenneth J Bloom
May 12, 2001·Critical Reviews in Clinical Laboratory Sciences·G J Tsongalis, A Ried
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H YamauchiD F Hayes
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R C BastUNKNOWN American Society of Clinical Oncology Tumor Markers Expert Panel
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rosana SáezGail M Clinton
Jul 13, 2004·Clinical Breast Cancer·Walter P CarneyChristopher P Price
Jul 19, 2002·Clinical Breast Cancer·Raquel Andrade Nunes, Lyndsay N Harris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

© 2021 Meta ULC. All rights reserved